Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Completed 17Recruiting 7Unknown 6Not yet recruiting 3Withdrawn 2Terminated 2Active not recruiting 2

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 5Observational 1

Sponsor

Cancer Type

Gastrointestinal 6

Conditions

Breast Neoplasms 64Colorectal Neoplasms 58Rectal Neoplasms 46Stomach Neoplasms 44Neoplasm Metastasis 16Pancreatic Neoplasms 15Colonic Neoplasms 13Triple Negative Breast Neoplasms 11Neoplasms 11Esophageal Neoplasms 9Nasopharyngeal Carcinoma 8Locally Advanced Rectal Cancer 7Esophageal Squamous Cell Carcinoma 7Cholangiocarcinoma 6Biliary Tract Neoplasms 6Carcinoma, Hepatocellular 5HER2 Positive Metastatic Breast Cancer 4Colorectal Cancer Metastatic 4Adenocarcinoma 4Solid Tumor 3Recurrence 3Gallbladder Neoplasms 3Anus Neoplasms 3Advanced Breast Cancer 3Squamous Cell Carcinoma of Head and Neck 2Solid Tumors 2Neuroendocrine Tumors 2Locally Advanced Colon Cancer 2Hyperthermia 2Head and Neck Neoplasms 2

Interventions

Gemcitabine 9Oxaliplatin 6Cisplatin 6Capecitabine 6durvalumab 4apatinib 4S 1 (combination) 4Irinotecan 4Immune Checkpoint Inhibitors 4surufatinib 3Injections 3Drug Therapy 3pembrolizumab 2lenvatinib 2camrelizumab 2Taxes 2Leucovorin 2Fluorouracil 2Docetaxel 2130-nm albumin-bound paclitaxel 2tremelimumab 1toripalimab 1taxane 1spartalizumab 1sintilimab 1regorafenib 1manganese chloride 1irinotecan sucrosofate 1gimeracil 1gemcitabine-oxaliplatin regimen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Unknown × Biliary Tract Neoplasms × Capecitabine × Clear all
NCT04856761 2022-08-18

A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

Fudan University

Unknown
160 enrolled
Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Recurrence, Cholangiocarcinoma

NCT04401709 2022-06-15

Gemcitabine+ Capecitabine Vs Capecitabine in Curatively Resected Biliary Tract Cancer

Samsung Medical Center

Phase 3 Unknown
490 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT04608786 2022-01-11

A Clinical Study of PD-L1 Antibody ZKAB001 Combined With Capecitabine in Resected Biliary Tract Cancer

Lee's Pharmaceutical Limited

Phase 1 Unknown
10 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT03873532 2020-02-13

A Trial Evaluating Surufatinib Efficacy and Safety in Biliary Tract Carcinoma Patients

Hutchmed

Phase 2/3 Unknown
298 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT02350686 2019-05-20

XELOX in Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy

Samsung Medical Center

Phase 2 Unknown
67 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT03609489 2018-08-09

A Study to Investigate Apatinib Combined Capecitabine on Adjuvant Therapy of Biliary Carcinoma

First Affiliated Hospital of Guangxi Medical University

Phase 2 Unknown
40 enrolled
Gastrointestinal

Biliary Tract Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡